Asako Nagata

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

Ping Chen, Nathan V. Lee, Wenyue Hu et al. · Molecular Cancer Therapeutics · 2016 · 414 citations

Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance

Phillip A. Schwartz, Petr Kuzmič, James Solowiej et al. · Proceedings of the National Academy of Sciences · 2013 · 271 citations · Full text

Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor

Kevin D. Freeman‐Cook, Robert L. Hoffman, Nichol Miller et al. · Cancer Cell · 2021 · 172 citations

Tumor Biology, Oncology, Cdk2/4/6 Inhibitor +10

Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer

Kevin D. Freeman‐Cook, Robert L. Hoffman, Douglas C. Behenna et al. · Journal of Medicinal Chemistry · 2021 · 112 citations · Full text

Discovery of <i>N</i>-((3<i>R</i>,4<i>R</i>)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1<i>H</i>-pyrazol-4-yl)amino)-9-methyl-9<i>H</i>-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR

Simon Planken, Douglas C. Behenna, Sajiv K. Nair et al. · Journal of Medicinal Chemistry · 2017 · 89 citations · Full text

Molecular Biology, Wild-type Egfr, Chemical Biology +21